ABBV-1088 / AbbVie - LARVOL DELTA

PINK1 activation by MTK458 ameliorates neurological impairments and pyroptosis after intracerebral hemorrhage in mice. (PubMed, Brain Res) - "It also reversed ICH-induced cortical cell pyroptosis by promoting Parkin/PINK1-mediated mitophagy and inhibiting NLRP3 inflammasome activation, as well as the expression of IL-1β and IL-18. These results suggest that MTK458 effectively reduces neurological impairments, brain edema, and anxiety-related behaviors in mice following ICH, highlighting PINK1 activation as a promising therapeutic strategy for ICH-induced neurological deficits."

Journal • Preclinical • Cerebral Hemorrhage • CNS Disorders • Cognitive Disorders • Hematological Disorders • Psychiatry • IL18 • IL1B • NLRP3 • PTEN

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline (PRNewswire) - "AbbVie...announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction that is believed to be a major contributing factor to Parkinson's disease pathogenesis and progression....Under the terms of the agreement, AbbVie will pay Mitokinin shareholders $110 million at closing for the acquisition of Mitokinin. Mitokinin shareholders remain eligible for potential additional payments of up to $545 million upon the achievement of certain development and commercial milestones related to the success of the PINK1 program, plus tiered royalties based on net sales."

M&A • Alzheimer's Disease • CNS Disorders • Huntington's Disease • Parkinson's Disease

SMALL MOLECULE PINK1 ACTIVATORS RESCUE MITOCHONDRIA-ASSOCIATED PATHOLOGY IN IDIOPATHIC PARKINSON'S DISEASE MODELS (ADPD 2023) - "Our data support the clini cal development of PINK1 activators as disease -modifying therapeutics for the treatment of idiopathic PD."

CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • PINK1